Skip to main content
Fig. 2 | EJNMMI Research

Fig. 2

From: Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo

Fig. 2

Imaging of hypoxia within CT26 tumour bearing mice (n = 13), PET-MRI ad Representative PET-MRI images showing the global co-localisation of FMISO uptake and BOLD MRI signal. Images were acquired 120 min post-injection of 10 MBq of [18F]-Fluoromisonidazole (FMISO). PET. a Representative maximum-intensity-projection FMISO PET Image; b Transversal slice showing FMISO uptake within the tumour; c T2*-weighted MRI and d BOLD image derived from T2* mapping. White dashed lines: tumour limits, white arrows: oxygenated tumour area (increased BOLD signal), black circle: hypoxic tumour areas (decreased BOLD signal). CLI (e): Representative FMISO CLI image of the same mouse as for a to d acquired just after the PET-MRI scan. f Tumour-to-background ratio for PET, MRI and CLI following the injection of FMISO determined by the ratio of the signal from the tumour and a contralateral irrelevant region of interest (muscle); n = 13, ***p < 0.001

Back to article page